肺炎支原体P1C-IL-2融合基因疫苗鼻饲对小鼠免疫效果的检测  

Protective immune responses induced by intranasal immunization with Mycoplasma pneumoniae P1C-IL-2 fusion DNA vaccine in mice

作　　者：朱翠明[1] 余敏君[1] 高顺利[2] 曾焱华[1] 游晓星[1] 吴移谋[1] 

机构地区：[1]南华大学医学微生物学与免疫学教研室,湖南衡阳421001 [2]南华大学附属第一医院,湖南衡阳421001

出　　处：《细胞与分子免疫学杂志》2013年第6期585-588,592,共5页Chinese Journal of Cellular and Molecular Immunology

基　　金：国家自然科学基金(81072418/H1005);湖南省教育厅重点实验室资助项目(2012年)

摘　　要：目的研究肺炎支原体(Mp)P1C-IL-2融合基因疫苗经鼻饲免疫小鼠后的免疫应答水平和免疫保护作用,了解IL-2对P1C核酸疫苗的免疫佐剂效应。方法将构建的P1C-IL-2核酸疫苗鼻饲免疫BALB/c鼠,ELISA检测免疫小鼠血清IgG滴度、IgG亚类和支气管肺泡灌洗液中IgA及IFN-γ、IL-4的水平;建立小鼠Mp感染模型,观察Mp攻击后小鼠肺组织炎症情况和支气管肺泡灌洗液中Mp菌落数的变化。结果 P1C-IL-2双基因疫苗组小鼠血清中的总IgG、IgG1、IgG2a亚类和支气管肺泡灌洗液中IFN-γ和IL-4水平均较P1C疫苗组小鼠显著增高(P<0.05),但两组支气管肺泡灌洗液IgA差异无显著性(P>0.05)。用Mp滴鼻感染免疫小鼠,第1、3、6天P1C-IL-2双基因融合疫苗组小鼠肺组织炎症病理评分显著高于P1C单基因疫苗免疫组小鼠,两组小鼠支气管肺泡灌洗液中的Mp菌落数差异无显著性(P>0.05)。结论 IL-2能显著增强P1C疫苗的免疫应答水平,但在感染早期也激发了较强的肺组织炎症。x Objective To investigate the immune responses and immune protections of a DNA vaccine constructed by fusing Mycoplasma pneumoniae （M. pneumoniae） pl gene car boxy terminal region （plc gene） with interleukin-2 （IL-2） gene. Methods BALB/c mice were immunized by intranasal inoculation of PIC-IL-2 fusion DNA vaccine. Levels of serum IgG, IgG isotypes, BAL fluids IgA, IFN-γ and IL-4 were detected by ELISA. We established the mouse models infected with M. pneumoniae, and then observed the histopathological changes in lungs and counted colonies in bronchoalveolar lavage fluid （BALF） after challenged intranasally with M. pneumoniae. Results Serum total IgG, IgG1 and IgG2a isotypes, levels of IFN-γ and IL-4 in BALF increased significantly in the group inoculated with P1C-IL-2 fusion DNA vaccine as compared with the one with P1C DNA vaccine （P〈0.05）, while there was no significant difference in BALF IgA between the two groups （P〉0.05）. The lung tissue inflammation was aggravated and the histopathologic score （HPS） of P1C-IL-2 DNA vaccine immunized mice significantly increased as compared with those in P1C DNA vaccine immunized mice at 1, 3, 6 d after challenged intranasally with M. pneumoniae （P〈0.05）. The P1C-IL-2 fusion DNA vaccine did not show significant difference from PIC DNA vaccine in the detectable number of M. pneumoniae strain in BALF（ P 〉 0.05）. Conclusion IL-2 can enhance the systemic immune responses of P1C DNA vaccine, but it also can develop a severe histopathological change in early days after infection of M. pneumoniae.

关 键 词：肺炎支原体 P1基因 基因疫苗 IL-2 

分 类 号：R392-33[医药卫生—免疫学] R518.9[医药卫生—基础医学]